Daunorubicin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1979
- First approval year
- 1979
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Daunorubicin
- Molecular weight
- 527.53
- Structure (SMILES)
- COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
- daunorubicin component of vyxeos
- Daunorubicin component of vyxeos
- daunoxome
- Daunoxome
- (1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE
- (8S,10S)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE
- 1s 3s 3 acetyl 1 2 3 4 6 11 hexahydro 3 5 12 trihydroxy 10 methoxy 6 11 dioxo 1 naphthacenyl 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranoside
- 5 12 naphthacenedione 8 acetyl 10 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranosyl oxy 7 8 9 10 tetrahydro 6 8 11 trihydroxy 1 methoxy 8s cis
- 5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-
- 8s 10s 8 acetyl 10 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranosyl oxy 6 8 11 trihydroxy 1 methoxy 7 8 9 10 tetrahydrotetracene 5 12 dione
- daunomycin
- Daunomycin
- DAUNOMYCIN [IARC]
- daunomycin iarc
- daunorubicin
- Daunorubicin
- DAUNORUBICIN [HSDB]
- daunorubicin [INN]
- DAUNORUBICIN [MART.]
- DAUNORUBICIN [MI]
- DAUNORUBICIN [ORANGE BOOK]
- DAUNORUBICIN [VANDF]
- Daunorubicin [WHO-DD]
- daunorubicin hsdb
- daunorubicin inn
- daunorubicin mart
- daunorubicin mi
- daunorubicin orange book
- daunorubicin vandf
And 29 more, listed on the interactive page.
- ATC classification codes
- L01DB02
Sources for recorded values
- CAS registry numbers
- 20830-81-3
- ChEMBL ID
- CHEMBL178
- InChIKey
- STQGQHZAVUOBTE-VGBVRHCVSA-N
- PubChem compound IDs
- 30323
- FDA ingredient codes (UNII)
- ZS7284E0ZP
- 3109
- 1364321
- Applicant
- JAZZ PHARMS THERAP
- Approval date
- 3 Aug 2017
- Application number
- NDA209401
- Patents
- 15
- Designations
- 0
- Earliest recorded loss of exclusivity
- 15 Apr 2033
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- daunorubicin
- Type
- Natural product
- Drug name stem
- -rubicin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
- Protein identifier
- P11388
Open Targets mechanisms
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TOP2A
- Protein identifier
- P11388
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Thrombocythemia, Essential
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000479
- Subject identifier
- D013920
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Polycythemia Vera
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002429
- Subject identifier
- D011087
- Condition
- Anemia, Refractory
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003802
- Subject identifier
- D000753
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Leukemia, Lymphoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004289
- Subject identifier
- D007945
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0000870
- Subject identifier
- D054198
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0000873
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004643
- Subject identifier
- D007951
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0044881
- Subject identifier
- D019337
- Condition
- Primary Myelofibrosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0044903
- Subject identifier
- D055728
- Condition
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0044917
- Subject identifier
- D054218
- Condition identifier
- EFO_0000198
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Condition identifier
- EFO_0000558
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 2
- Condition identifier
- HP_0002863
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000814
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000870
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000872
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000873
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000873
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003539
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004643
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004643
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004947
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004952
- Condition identifier
- MONDO_0004963
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005055
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005059
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
And 29 more, listed on the interactive page.
- Warning
- Black Box Warning
- Country
- United States
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Event
- acute lymphocytic leukaemia recurrent
- Reports
- 32
- Reporting signal score
- 93.5551
- Event
- acute myeloid leukaemia
- Reports
- 46
- Reporting signal score
- 78.4634
- Event
- acute myeloid leukaemia recurrent
- Reports
- 19
- Reporting signal score
- 60.4517
- Event
- alanine aminotransferase increased
- Reports
- 100
- Reporting signal score
- 60.8611
- Event
- aplasia
- Reports
- 24
- Reporting signal score
- 57.2943
- Event
- arthralgia
- Reports
- 13
- Reporting signal score
- 52.2417
- Event
- aspergillus infection
- Reports
- 45
- Reporting signal score
- 107.672
- Event
- bacteraemia
- Reports
- 57
- Reporting signal score
- 99.1039
- Event
- blood bilirubin increased
- Reports
- 60
- Reporting signal score
- 56.25
- Event
- blood culture positive
- Reports
- 28
- Reporting signal score
- 62.9301
- Event
- blood fibrinogen decreased
- Reports
- 22
- Reporting signal score
- 70.4759
- Event
- bone marrow failure
- Reports
- 97
- Reporting signal score
- 141.911
- Event
- bronchopulmonary aspergillosis
- Reports
- 39
- Reporting signal score
- 80.1652
- Event
- candida infection
- Reports
- 46
- Reporting signal score
- 73.9843
- Event
- cardiotoxicity
- Reports
- 44
- Reporting signal score
- 78.1569
- Event
- cerebral venous thrombosis
- Reports
- 31
- Reporting signal score
- 86.4944
- Event
- clostridium difficile colitis
- Reports
- 39
- Reporting signal score
- 57.2145
- Event
- coagulopathy
- Reports
- 44
- Reporting signal score
- 61.0014
- Event
- colitis
- Reports
- 101
- Reporting signal score
- 133.77
- Event
- dizziness
- Reports
- 27
- Reporting signal score
- 51.2913
- Event
- fatigue
- Reports
- 49
- Reporting signal score
- 60.4446
- Event
- febrile bone marrow aplasia
- Reports
- 76
- Reporting signal score
- 206.985
- Event
- febrile neutropenia
- Reports
- 605
- Reporting signal score
- 1,431.65
- Event
- haematotoxicity
- Reports
- 119
- Reporting signal score
- 304.735
- Event
- hepatocellular injury
- Reports
- 54
- Reporting signal score
- 51.9169
And 21 more, listed on the interactive page.
- NCT00002093
- NCT00002925
- NCT00005793
- NCT00049517
- NCT00085709
- NCT00109837
- NCT00129168
- NCT00613457
- NCT00651261
- NCT01117441
- NCT01890746
- NCT01920737
- NCT02660762
- NCT03826992
- NCT06182592
- NCT00111345
- NCT00130195
- NCT00131027
- NCT00137111
- NCT00176462
- NCT00184041
- NCT00187005
- NCT00549848
- NCT01004497
- NCT02003222
And 139 more, listed on the interactive page.
- Dose
- 44 mg/m2 for induction; 29 mg/m2 for consolidation
- Route
- Intravenous
- How often
- Days 1, 3, and 5 for first induction; days 1 and 3 for second induction; days 1 and 3 for consolidation
- Hydrogen bond acceptors
- 11
- Hydrogen bond donors
- 5
- Polar surface area
- 185.84
- Calculated partition coefficient (ALogP)
- 1.03
- Calculated partition coefficient (XLogP)
- 1.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 4
- Heavy atoms
- 38
- Molecular formula
- C27H29NO10
- Monoisotopic mass
- 527.17914612
- Natural product
- Yes
- 68727-745
- Recorded assays
- 3,287
- Active assays
- 747
- Confirmatory
- Other
- Screening
- Summary
- Antibiotics, Antineoplastic
- Topoisomerase II Inhibitors
These details could not be displayed.
Related records
Trials (179)
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
- A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
- A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
- A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
- A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia
- A Safety and Efficacy Study of Eltrombopag in Subjects With AML
- A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
- A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
- A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Approved for (2)
- Acute myeloid leukemia
- Neoplasm
In development for (18)
- Acquired polycythemia vera Phase 1
- Acute lymphoblastic leukemia Phase 3
- B-cell acute lymphoblastic leukemia Phase 1
- Childhood acute lymphoblastic leukemia Phase 3
- Chronic hepatitis B virus infection Phase 3
- Chronic myeloid leukemia Phase 1
- Essential thrombocythemia Phase 1
- Hematopoietic and lymphoid cell neoplasm Phase 1
- Kaposi's sarcoma Phase 3
- Leukemia Phase 3
- Lymphoblastic lymphoma Phase 3
- Lymphoid leukemia Phase 2
- Myelodysplastic syndrome Phase 2
- Myelodysplastic syndrome with single lineage dysplasia Phase 2
- Myelofibrosis Phase 1
- Myeloid leukemia Phase 3
- Non-Hodgkin lymphoma Phase 3
- T-lymphoblastic lymphoma Phase 3
Other linked conditions (1)
- Acute myeloid leukemia by FAB classification
Targets (1)
- TOP2A DNA topoisomerase II alpha inhibitor